\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[greek,ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Investigation of Vital Organ Specific Biomarkers Using Cell-Based Assays
after Treatment with the Biofield Energy Treated Test Formulation}



\author[1]{Peoples JJ}%
\author[1]{Mahendra Kumar Trivedi}%
\author[1]{Alice Branton}%
\author[1]{Dahryn Trivedi}%
\author[1]{Gopal Nayak}%
\author[1]{Mayank Gangwar}%
\author[1]{Snehasis Jana}%
\affil[1]{Affiliation not available}%


\vspace{-1em}



  
  \date{May 18, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
The present study aimed to determine the impact of the Biofield Energy
Treated test formulation and different cell line mediums on vital organs
function. Specific cell based assays were performed based on the vital
organs function (bones, heart, liver, lungs, and brain). The test item
(TI) and cell line media was divided into two parts; one was untreated
(UTTI) and other part received the Biofield Energy Treatment remotely by
a renowned Biofield Energy Healer, James Jeffrey Peoples, USA and were
labeled as the Biofield Energy Treated (BT) test formulation/media. The
test formulation was tested against various activities using cell line
assay in their specific medium (Med). The test formulation was tested
for cell viability, and the results showed that the test formulation at
tested concentrations was found non-toxic against all the cell lines.
Cytoprotective action of the test formulation showed a significant
restoration of cell viability by 48.3\% (at 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 9.3\% (at 1
\selectlanguage{greek}μ\selectlanguage{english}g/mL), and 64.1\% (at 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in the UT-Med + BT-TI, BT-Med +
UT-TI, and BT-Med + BT-TI groups respectively, as compared to the
untreated test group in human cardiac fibroblasts cells (HCF) cells,
while 48.3\% (at 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 9.3\% (at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 64.1\% (at 25.5
\selectlanguage{greek}μ\selectlanguage{english}g/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups
respectively, as compared to the untreated test group. However,
cytoprotective activity in human hepatoma cells (HepG2) showed improved
cell viability by 65.4\% (at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 63.8\% (at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 39.4\%
(at 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med +
BT-TI groups respectively, as compared to the untreated test group. In
addition, cytoprotective activity in adenocarcinomic human alveolar
basal epithelial cells (A549) showed improved cell viability by 28.4\%
(at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 101.7\% (at 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 181.7\% (at 0.1 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in
the UT-Med + BT-TI, BTMed + UT-TI, and BT-Med + BT-TI groups
respectively, as compared to the untreated test group. ALP activity in
MG-63 cells was maximum increased by 88.1\% at 50 \selectlanguage{greek}μ\selectlanguage{english}g/mL in the BT-Med +
BT-TI group, while in Ishikawa cells showed maximum increased ALP
activity by 433.3\% and 136.1\% at 0.1 and 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL respectively, in the
BT-Med + BT-TI group as compared to the untreated group. The maximum
percent cellular protection of HCF (heart) cells (decreased of LDH
activity) was significantly increased by 87.8\% at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL in the UT-Med
+ BT-TI group, while BT-Med + UT-TI group showed increased protection by
40.1\% at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL, and improved cellular protection by 70.1\% at 1
\selectlanguage{greek}μ\selectlanguage{english}g/mL in the BTMed + BT-TI group as compared to the untreated test
group. Alanine amino transferase (ALT) in terms of percent protection of
HepG2 (liver) cells (decreased of ALT activity) was reported by 35.6\%
(at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 19\% (at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 61.2\% (at 63.75 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in the
UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively,
as compared to the untreated test group. Cellular protection of A549
(lungs) cells (increased of SOD activity) in terms of percentage was
increased by 102.3\% (at 1 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 10.3\% (at 25.5 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 38.4\%
(at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI
groups, respectively as compared to untreated group. Serotonin level was
significantly increased by 23.7\% (at 0.1 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 36.8\% (at 25 \selectlanguage{greek}μ\selectlanguage{english}g/mL),
and 51.9\% (at 25 \selectlanguage{greek}μ\selectlanguage{english}g/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and
BT-Med + BT-TI groups, respectively compared to untreated test group in
human neuroblastoma cells (SH-SY5Y). However, the relative
quantification (RQ) of vitamin D receptor (VDR) was significantly
increased by 471\% (at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), 318.9\% (at 10 \selectlanguage{greek}μ\selectlanguage{english}g/mL), and 326.2\% (at
50 \selectlanguage{greek}μ\selectlanguage{english}g/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI
groups, respectively as compared to the untreated in MG-63 cells. In
conclusion, Biofield Energy treated test formulation (The Trivedi
Effect\selectlanguage{ngerman}®) would be significantly useful for multiple organ health that
can be used against coronary artery disease, arrhythmias, congenital
heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis,
asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.%
\end{abstract}\selectlanguage{ngerman}%



\sloppy


\textbf{Journal Name:}~Cell \& Cellular Life Sciences Journal (CCLSJ)

\textbf{Date of Publication:}~16-07-2019

\textbf{ISSN:}~2578-4811

\textbf{Volume:}~4

\textbf{Issue:}~2

\textbf{\textbf{Journal Web
URL:}}~\url{https://medwinpublishers.com/CCLSJ/volume.php?volumeId=243\&issueId=724}

\textbf{~\textbf{Journal PDF
URL:}}~\url{https://medwinpublishers.com/CCLSJ/CCLSJ16000144.pdf}

\textbf{Publisher:}~Medwin

\textbf{Keywords:}~The Trivedi Effect\selectlanguage{ngerman}®; Biofield Energy Treatment; Organ
Health; Cardiac Health; Liver Health; Lungs Health; Multiple Organ
Failure; Bone Health

\textbf{Citation:}~Peoples JJ, et al. Investigation of Vital Organ
Specific Biomarkers Using Cell-Based Assays after Treatment with the
Biofield Energy Treated Test Formulation. Cell Cellular Lif Sci J 2019,
4(2): 000145.

\selectlanguage{english}
\FloatBarrier
\end{document}

